Prognostic impact of cardiohepatic syndrome in patients with ST-segment elevation myocardial infarction


Sungur M. A., Sungur A., KARAGÖZ A., Can F., Yllmaz M. F., Zeren G., ...Daha Fazla

Biomarkers in Medicine, cilt.17, sa.2, ss.111-121, 2023 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 17 Sayı: 2
  • Basım Tarihi: 2023
  • Doi Numarası: 10.2217/bmm-2022-0770
  • Dergi Adı: Biomarkers in Medicine
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Chemical Abstracts Core, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.111-121
  • Anahtar Kelimeler: cardiohepatic syndrome, in-hospital mortality, long-term mortality, ST-segment elevation myocardial infarction
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Background: Cardiohepatic syndrome (CHS) indicates a bidirectional interaction between the heart and liver. This study was designed to evaluate the impact of CHS on in-hospital and long-term mortality in patients with ST-segment elevation myocardial infarction (STEMI) who underwent primary percutaneous coronary intervention. Materials & methods: 1541 consecutive STEMI patients were examined. CHS was defined as the elevation of at least two of three cholestatic liver enzymes: total bilirubin, alkaline phosphatase and gamma-glutamyl transferase. Results: CHS was present in 144 (9.34%) patients. Multivariate analyses revealed CHS as an independent predictor of in-hospital (odds ratio: 2.48; 95% CI: 1.42-4.34; p = 0.001) and long-term mortality (hazard ratio: 2.4; 95% CI: 1.79-3.22; p < 0.001). Conclusion: The presence of CHS is a predictor of poor prognosis in patients with STEMI and should be evaluated during the risk stratification of these patients.